Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thalidomide - Celgene Corporation

Drug Profile

Thalidomide - Celgene Corporation

Alternative Names: Alpha-N-phthalimidoglutarimide; CC-2001; FPF-300; K-17; NSC-66847; Synovir; Thaled; Thalidomide Celgene; Thalidomide Pharmion; Thalomid

Latest Information Update: 10 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EntreMed; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA); University of Pennsylvania
  • Developer Celgene Corporation; Erkim; Fujimoto Pharmaceutical; Laphal; Weill Cornell Medical College
  • Class Antileprotics; Antineoplastics; Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Cachexia; Multiple myeloma; Aphthous stomatitis; Crohn's disease; Leprosy; Kaposi's sarcoma; Mycobacterial infections; Myelodysplastic syndromes; Brain cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leprosy; Multiple myeloma
  • Phase II Waldenstrom's macroglobulinaemia
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 18 Dec 2018 Celgene completes an expanded-access programme in USA (PO) (NCT03723083)
  • 29 Oct 2018 Celgene initiates an expanded-access programme in USA (PO) (NCT03723083)
  • 20 Jul 2018 Celgene completes a phase I/II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT00966693)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top